PsychedelicNewsBreaks – From San Francisco to Serbia: Global Psychedelic Week Sparks Worldwide Connection 

Global Psychedelic Week (GPW) 2025, taking place Nov. 3–9, 2025, marks the world’s first distributed psychedelic conference, connecting over 5,000 participants across 100 countries through a hybrid model of online and in-person gatherings. Featuring more than 100 leading voices—including Rick Doblin, Robin Carhart-Harris, and Dr. Pamela Kryskow—GPW’s powerful vision is to create a global dialogue on psychedelic science, therapy, and culture. Nearly 60 local events in countries such as India, Serbia, Jamaica, Colombia, and Argentina will foster community-based connection.

“During Global Psychedelic Week, over 100 in-person events will take place around the world. We’re decentralizing the conversation and meeting people where they are, in their own communities. Rather than gathering in a single location, we’re fostering the space for local connection, reflection, and dialogue. These gatherings feature deeper engagement rooted in local culture and relationships. This is how a truly global movement grows, from the ground up.” —Milica Radovic Mandic, Co-founder, Global Psychedelic Week.

To view the full article, visit https://ibn.fm/dPxYF

About Global Psychedelic Week

Global Psychedelic Week is the world’s first distributed psychedelic conference, uniting thousands of participants across continents through seven days of thematic programming, 100+ speakers, and dozens of in-person events worldwide. By blending global access with local engagement, GPW creates an inclusive platform spotlighting the voices shaping the future of psychedelic healing, science, and culture.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
Austin, Texas
www.PsychedelicNewsWire.com
512.354.7000 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway 

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S.…

4 days ago

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising.…

4 days ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has licensed regulatory-grade real-world evidence drawn from more than…

1 month ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet…

2 months ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug…

3 months ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated…

3 months ago